11,101 Shares in Zoetis Inc. $ZTS Bought by Inceptionr LLC

Inceptionr LLC purchased a new position in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,101 shares of the company’s stock, valued at approximately $1,397,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank bought a new stake in Zoetis during the fourth quarter valued at $734,425,000. Vanguard Group Inc. increased its stake in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. Nordea Investment Management AB increased its stake in Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. Montrusco Bolton Investments Inc. increased its stake in Zoetis by 256.7% during the fourth quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock valued at $266,888,000 after purchasing an additional 1,560,314 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in Zoetis by 83.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after purchasing an additional 1,227,085 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of several recent research reports. BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Citigroup lowered their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Morgan Stanley reiterated an “overweight” rating and set a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Finally, Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $133.92.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Bank of America Securities reportedly maintained a Hold rating on Zoetis, which may provide some support by suggesting analysts are not turning more negative on the stock. Bank of America Securities Remains a Hold on Zoetis (ZTS)
• Neutral Sentiment: Some commentary notes that Zoetis may look inexpensive, but frames that valuation in the context of weaker fundamentals and legal concerns, making the stock’s appeal less clear-cut. Zoetis Might Be Cheap For A Reason
• Negative Sentiment: Multiple firms, including Rosen, Schall, DJS, and others, reiterated or promoted a securities-fraud class action against Zoetis, with deadlines for lead-plaintiff motions approaching. That ongoing litigation overhang is a clear negative for investor sentiment. Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS

Insider Buying and Selling

In related news, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 11,650 shares of company stock valued at $886,384 over the last 90 days. 0.22% of the stock is currently owned by company insiders.

Zoetis Stock Down 1.0%

Zoetis stock opened at $81.38 on Thursday. The company has a 50-day simple moving average of $98.43 and a 200-day simple moving average of $114.75. The firm has a market capitalization of $34.12 billion, a P/E ratio of 13.50, a P/E/G ratio of 1.28 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a one year low of $72.38 and a one year high of $168.83.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. Zoetis’s dividend payout ratio is currently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.